RxDoctor Payments Data

Mohammad Alam, MD

Endocrinology, Diabetes & Metabolism · Terre Haute, INNPI 1972577591

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,343 of the $28,458 with a category attached, or 92.6%. Sanofi-aventis U.S. LLC accounts for 96.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $18,792 and has fallen 98.4% since, to $307 in 2025.

$28,458in general payments, 2019–2025

Across 77 payments — averaging $369.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$28K
  • Dexcom, Inc.$385
  • Medtronic$310
  • Amgen$63
  • Lilly USA, LLC$30
  • Roche Diabetes Care, Inc.$30
  • plus $63 from 4 others

What the payments were for

  • Speaking & faculty fees$26,34393%
  • Travel & lodging$7092%
  • Food & beverage$1,3775%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,458 in reported general payments places this provider in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.

See all endocrinology, diabetes & metabolism providers in Indiana

Medicare billing

Part B allowed, 2024
$157,635
Medicare patients
243
Services billed
1,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide585$668,780
Humulin R U-500 KwikpenInsulin Regular, Human170$365,501
OzempicSemaglutide207$291,367
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog150$126,383
JardianceEmpagliflozin69$99,662
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog160$88,942
Humalog Kwikpen U-100Insulin Lispro150$52,680
Humulin R U-500Insulin Regular, Human12$51,015
TradjentaLinagliptin32$36,088
Insulin Lispro Kwikpen U-100Insulin Lispro90$34,041
Novolog FlexpenInsulin Aspart97$32,685
Fiasp FlextouchInsulin Aspart (Niacinamide)28$31,374
TrulicityDulaglutide21$22,201
Tresiba Flextouch U-100Insulin Degludec32$20,624
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic128$16,967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$30$706,776662 claims
Boehringer IngelheimJardiance, Tradjenta$28$135,750101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.

Other endocrinology, diabetes & metabolism in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →